Researchers have uncovered a novel Rheumatoid Arthritis drug treatment method that directly targets the cells responsible for cartilage damage in the joints.

A specific rheumatoid arthritis drug that directly targets damage-causing cells may sound too good to be true but it is not science fiction. Researchers from the La Jolla Institute for the Allergy and Immunology and their colleagues from the University of California San Diego have the uncovered a novel Rheumatoid Arthritis drug therapy that specifically focuses on the kinds of the cells that are responsible for the cartilage damage in the affected joints of rheumatoid arthritis patients.

Their findings, published in the current issue of the Science Translational Medicine, have the potential to the unleash a whole new world of rheumatoid arthritis medicines that could alleviate symptoms and improve the disease outlook with the less complicated side effects. While current rheumatoid arthritis pharmaceuticals focus on the immune systems, this new class of the therapies would work on a different target to slow disease progression, prevent severe joint damage, and reduce inflammation without slowing or suppressing the immune system like many treatments do.“Unfortunately, for around 40 percent of patients, immune-targeted therapies are not sufficient to bring them into full remission,” said Bottini. “If we could add a drug that acts on a different target without increasing immune suppression it could be very valuable.”